Figure 1. Concentrations of sgp130 in serum and AqH from patients with T2DM and non-diabetic controls. Soluble gp130 (sgp130) was measured with multiplex bead immunoassay in serum (A) and aqueous humor (AqH; B) from controls (n = 51), non-diabetic retinopathy (NDR, n = 47), nonproliferative diabetic retinopathy (NPDR, n = 52), and proliferative diabetic retinopathy (PDR, n = 53). All groups were compared using the Kruskal–Wallis test followed by the Dunn multiple comparison test. The relationship between sgp130 in AqH and serum was tested, when matched samples were available, with the Spearman correlation (C). *p<0.001.